Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 2.57
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Data is available to registered users only
Buy
Sell